Travere Therapeutics, Inc.
TVTX
$62.04
$0.610.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 77.12% | 96.03% | 110.46% | 114.22% | 87.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.12% | 96.03% | 110.46% | 114.22% | 87.94% |
| Cost of Revenue | 8.46% | 10.06% | 7.62% | 9.64% | 5.54% |
| Gross Profit | 270.65% | 677.65% | 3,029.43% | 980.79% | 256.52% |
| SG&A Expenses | 41.22% | 27.15% | 17.80% | 8.03% | -0.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.22% | 18.98% | 13.12% | 8.78% | 2.16% |
| Operating Income | 76.30% | 74.65% | 75.48% | 67.92% | 46.03% |
| Income Before Tax | 60.33% | 80.17% | 84.63% | 74.61% | 55.86% |
| Income Tax Expenses | 723.71% | 2,690.63% | 723.33% | -101.92% | -127.25% |
| Earnings from Continuing Operations | 59.95% | 79.80% | 84.32% | 74.63% | 55.93% |
| Earnings from Discontinued Operations | 44,127.27% | 3,082.14% | 2,801.09% | 100.16% | -100.02% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.29% | 90.55% | 92.06% | 74.81% | -15.86% |
| EBIT | 76.30% | 74.65% | 75.48% | 67.92% | 46.03% |
| EBITDA | 119.01% | 109.01% | 99.02% | 85.33% | 56.18% |
| EPS Basic | 77.56% | 91.84% | 92.89% | 77.02% | -8.73% |
| Normalized Basic EPS | 64.43% | 82.37% | 82.75% | 70.67% | 49.19% |
| EPS Diluted | 76.94% | 91.39% | 92.58% | 76.73% | -8.76% |
| Normalized Diluted EPS | 62.57% | 81.01% | 81.58% | 69.60% | 49.19% |
| Average Basic Shares Outstanding | 7.89% | 10.28% | 13.09% | 13.19% | 10.01% |
| Average Diluted Shares Outstanding | 11.85% | 14.38% | 17.33% | 17.53% | 10.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |